PIN8 COST EFFECTIVENESS OF THE MF59-ADJUVANTED INFLUENZA VACCINE IN FRANCE:THE “AT-RISK” ADULT POPULATION
نویسندگان
چکیده
منابع مشابه
Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
BACKGROUND The aim of the present study was to estimate the effectiveness of the MF59™-adjuvanted influenza A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk population and persons over 60 in the Netherlands. METHODS We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November 2009 ...
متن کاملEconomic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France
Modelling A cohort model was used to assess the costs and consequences of adjuvanted vaccine against influenza in comparison with standard non-adjuvanted vaccination in the high-risk elderly. The model considered the attack rate in the relevant population, and subsequent cases, general practitioner (GP) visits, hospital admissions and deaths. Adverse events were not considered. The time horizon...
متن کاملFluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere. Conventional inactivated influenza vaccine (IIV) is less immunogenic and effica...
متن کاملPharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
INTRODUCTION Influenza vaccination has proven effective in the reduction of influenza-like illness (ILI) cases and influenza-related hospitalizations, drug consumption, primary care consultations and deaths in the elderly population. The aim of this study is the assessment of the financial budget impact of a seasonal vaccination program based on the use of the MF59 adjuvanted vaccine as compare...
متن کاملTrial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
BACKGROUND The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority. METHODS We conducted a single-center study, involving 176 adults, 18 to 50 years of age, to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted and nonadjuvanted for...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2007
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)65515-5